Mastodon

Regulax® Picosulfate (Tablets, Drops) Instructions for Use

ATC Code

A06AB08 (Sodium picosulfate)

Active Substance

Sodium picosulfate (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Laxative drug that stimulates intestinal peristalsis

Pharmacotherapeutic Group

Laxative

Pharmacological Action

Laxative. Under the action of intestinal microorganisms, it is hydrolyzed to form an active form, which causes irritation of the receptors of the intestinal mucosa and enhances its peristalsis.

It promotes the accumulation of water and electrolytes in the large intestine, which leads to stimulation of the act of defecation, reduction of evacuation time, and softening of the stool.

Pharmacokinetics

After oral administration, it is not absorbed from the gastrointestinal tract and does not undergo enterohepatic circulation.

In the distal part of the large intestine, sodium picosulfate is cleaved to form the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane.

The time to onset of the laxative effect is determined by the rate of release of the active metabolite and is 6-12 hours.

Approximately 10.4% of the total dose is excreted by the kidneys as a glucuronide within 48 hours.

Indications

Constipation due to atony and hypotension of the colon (including in the elderly, in bedridden patients, after surgery, after childbirth, and during lactation); constipation caused by medication; constipation due to intestinal dysbiosis, dietary disorders; for regulating stool in hemorrhoids, proctitis, anal fissures; gallbladder diseases, irritable bowel syndrome with predominant constipation.

ICD codes

ICD-10 code Indication
K59.0 Constipation
K60 Fissure and fistula of anus and rectum
K62.8 Other specified diseases of anus and rectum (including proctitis)
K64 Hemorrhoids and perianal venous thrombosis
Z51.4 Preparatory procedures for subsequent treatment or examination, not elsewhere classified
ICD-11 code Indication
DB32.1 Slow-transit constipation
DB50.Z Fissure or fistula of anal region, unspecified
DB6Z Hemorrhoids or perianal venous diseases, unspecified
DB70.Z Infections of anal and rectal regions, unspecified
DB72.Z Some specified diseases of the anal canal, unspecified
DD91.1 Functional constipation
DE2Z Diseases of the digestive system, unspecified
EG61 Infections of the anus or perianal skin
QB9A Preparatory procedures for subsequent treatment

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer orally. Determine the dose individually based on patient age and clinical response.

For adults and children over 10 years, the typical dose is 10-20 mg (5-10 ml of drops or 1-2 tablets) taken once daily.

For children 4 to 10 years, administer 5-10 mg (2.5-5 ml of drops) once daily. For children under 4 years, use only the drop formulation at a dose of 0.15-0.3 mg/kg body weight; calculate the exact volume carefully.

Take the dose in the evening before bedtime. The laxative effect typically occurs after 6 to 12 hours.

For oral drops, use the provided measuring dropper. Mix the dose with a small amount of water or juice immediately before administration.

Do not use for more than 10 consecutive days without medical supervision. Prolonged use can lead to electrolyte imbalance and dependence.

If constipation persists despite treatment, discontinue use and consult a physician to investigate the underlying cause.

Initiate therapy with the lowest effective dose. Adjust the dose to achieve soft, formed stool no more than once or twice daily.

Adverse Reactions

From the digestive system dyspepsia, flatulence, nausea, vomiting, abdominal cramps and pain, diarrhea.

From the nervous system dizziness, fainting, drowsiness, increased fatigue.

From the immune system allergic reactions, angioedema, allergic dermatitis.

From the skin and subcutaneous tissues skin rash, urticaria, itching.

From metabolism increased excretion of potassium, sodium and other electrolytes, dehydration.

Contraindications

Hypersensitivity to sodium picosulfate; intestinal obstruction or obstructive bowel diseases; acute diseases of the abdominal organs or severe abdominal pain that may be accompanied by nausea, vomiting, fever, including appendicitis; acute inflammatory bowel diseases; severe dehydration; first trimester of pregnancy; childhood – depending on the dosage form.

With caution elderly age, hypokalemia, increased blood magnesium concentration, asthenia, renal failure.

Use in Pregnancy and Lactation

Contraindicated for use in the first trimester of pregnancy. Use in the second and third trimesters of pregnancy should only be if the intended benefit to the mother outweighs the possible risk to the fetus.

The active metabolite and its glucuronides are not excreted in breast milk. It is possible to use during lactation (breastfeeding) according to indications in recommended doses.

Use in Renal Impairment

Should be used with caution in patients with impaired renal function.

Pediatric Use

It is possible to use in children according to indications, in age-appropriate recommended doses and dosage forms. It is necessary to strictly follow the instructions in the sodium picosulfate drug labels regarding contraindications for use in children of different ages for specific sodium picosulfate dosage forms.

Geriatric Use

Should be used with caution in elderly patients.

Special Precautions

The product is tasteless, so it can be added to food for children. Do not use daily without medical supervision for more than 10 days.

Dizziness and fainting that occur after taking sodium picosulfate may be associated with a vasovagal reaction (e.g., straining during defecation, abdominal cramps).

The possibility of spontaneous defecation cannot be excluded. If the nature of the stool does not change for a long time while taking sodium picosulfate, it is necessary to consult a doctor to determine the cause of constipation.

Studies on the effect of sodium picosulfate on fertility have not been conducted. No teratogenic effects were identified.

Effect on ability to drive vehicles and operate machinery

If vasovagal reactions occur in patients while taking the product, they should avoid driving vehicles and engaging in other activities that require high concentration and speed of psychomotor reactions.

Drug Interactions

With simultaneous use with broad-spectrum antibiotics, a decrease in the laxative effect of sodium picosulfate is possible.

With simultaneous use with diuretics, with corticosteroids, an increased risk of electrolyte disturbances is possible.

Electrolyte imbalance that occurs while taking sodium picosulfate in high doses may lead to a deterioration in the tolerability of cardiac glycosides with their simultaneous use.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Krewel Meuselbach, GmbH (Germany)

Dosage Form

Bottle OTC Icon Regulax® Picosulfate Oral drops 7.5 mg/1 ml: bottle 10 ml, 20 ml or 50 ml with dropper cap

Dosage Form, Packaging, and Composition

Oral drops in the form of a transparent, colorless solution.

1 ml
Sodium picosulfate monohydrate 7.5 mg

Excipients : sorbitol liquid (non-crystallizing), propylene glycol, purified water.

10 ml – dark glass bottles with a dropper cap (1) – cardboard boxes.
20 ml – dark glass bottles with a dropper cap (1) – cardboard boxes.
50 ml – dark glass bottles with a dropper cap (1) – cardboard boxes.

Marketing Authorization Holder

Krewel Meuselbach, LLC (Russia)

Manufactured By

PharmVILAR NPO, LLC (Russia)

Dosage Form

Bottle OTC Icon Regulax® Picosulfate Tablets 10 mg: 10, 20, or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, flat-cylindrical, with a score on one side and a bevel on two sides.

1 tab.
Sodium picosulfate monohydrate 10.37 mg,
   Which corresponds to the sodium picosulfate content 10 mg

Excipients : sodium starch glycolate (type C), microcrystalline cellulose (type 102), magnesium stearate.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.

TABLE OF CONTENTS